Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Fruquintinib & Colorectal Cancer (CRC), Fruquintinib is approved for metastatic colorectal cancer by the FDA, and (as of late 2024–2025) EMA review and European use are emerging but not as advanced as U.S. and Chinese approvals (1, 2, 3, 4)
The clinical phase III trial, identified as NCT04322539, demonstrated that treatment with Fruquintinib led to a significant and clinically meaningful improvement in overall survival when compared to a placebo in patients suffering from refractory metastatic colorectal cancer. This evidence supports the consideration of Fruquintinib as a worldwide treatment option for individuals with this condition. Further…